Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS

Go back to Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS
(AMEX: MKKGY) Delayed: 36.42 -0.98 (2.62%)
Previous Close $37.40    52 Week High
Open $37.04    52 Week Low
Day High $37.05    P/E N/A 
Day Low $36.36    EPS
Volume 153,025       

Merck & Co. (NYSE: MRK) Delayed: 76.61 +0.91 (1.20%)
Previous Close $75.70    52 Week High $65.46 
Open $76.22    52 Week Low $47.97 
Day High $77.55    P/E 52.12 
Day Low $76.19    EPS $1.47 
Volume 17,573,409